News
Kaltura Bets on Agentic AI to Drive Next-Gen Video Growth
Key Points
- Interested in Kaltura, Inc.? Here are five stocks we like better.
- Kaltura is expanding into agentic AI, combining its video infrastructure with conversational AI, avatars
InspireMD, Inc. (NSPR) Reports Q2 Loss, Beats Revenue Estimates
InspireMD, Inc. (NSPR) came out with a quarterly loss of $0.17 per share versus the Zacks Consensus Estimate of a loss of $0.2. This compares to a loss of $0.26 per share a year ago. These figures
New Era Energy & Digital, Inc. (NUAI) Reports Q2 Loss, Misses Revenue Estimates
New Era Energy & Digital, Inc. (NUAI) came out with a quarterly loss of $0.18 per share versus the Zacks Consensus Estimate of a loss of $0.09. This compares to a loss of $0.21 per share a year ago
HIVE Digital Technologies (HIVE) Reports Q1 Loss, Lags Revenue Estimates
HIVE Digital Technologies (HIVE) came out with a quarterly loss of $0.19 per share versus the Zacks Consensus Estimate of a loss of $0.21. This compares to a loss of $0.06 per share a year ago
You Don't Need Millions to Want a Prenup
MongoDB (MDB) Dips More Than Broader Market: What You Should Know
MongoDB (MDB) closed the most recent trading day at $460.33, moving -2.53% from the previous trading session. This change lagged the S&P 500's 0.17% loss on the day. Elsewhere, the Dow lost 0.2%
AI Infrastructure Stocks: Billions of Reasons to Stay Bullish
The AI spending race shifted into a higher gear during this earnings season, with Microsoft, Amazon, Alphabet and Meta reporting roughly $170 billion in capital expenditures (CapEx).
Microsoft
OrthoPediatrics Sees ‘Inflection Point’ as New Products Fuel Record Quarter
Key Points
- Interested in OrthoPediatrics Corp.? Here are five stocks we like better.
- OrthoPediatrics reported a record second quarter, with approximately 15.5% revenue growth, improved
Sidus Space Q2 Earnings Call Highlights
Key Points
- Interested in Sidus Space, Inc.? Here are five stocks we like better.
- Second-quarter revenue fell 54% to approximately $583,000, while the net loss narrowed to $4.8 million; adjusted
Movano Q2 Earnings Call Highlights
Key Points
- Interested in Movano Inc.? Here are five stocks we like better.
- Corvex reported $3.8 million in Q2 2026 revenue, all from its AI platform and services business, while contracted
Solana Q2 Earnings Call Highlights
Key Points
- Interested in Solana Company? Here are five stocks we like better.
- Revenue reached $2.5 million in Q2 2026, entirely driven by staking rewards, while the company posted a $30.3
Here's Why SentinelOne (S) Fell More Than Broader Market
SentinelOne (S) closed at $23.11 in the latest trading session, marking a -3.06% move from the prior day. This move lagged the S&P 500's daily loss of 0.17%. Meanwhile, the Dow lost 0.2%, and the
Delta Air Lines (DAL) Dips More Than Broader Market: What You Should Know
Delta Air Lines (DAL) ended the recent trading session at $89.20, demonstrating a -2.31% change from the preceding day's closing price. The stock's change was less than the S&P 500's daily loss of
Synopsys (SNPS) Gains As Market Dips: What You Should Know
In the latest close session, Synopsys (SNPS) was up +2.37% at $421.50. The stock exceeded the S&P 500, which registered a loss of 0.17% for the day. At the same time, the Dow lost 0.2%, and the
Nutanix (NTNX) Sees a More Significant Dip Than Broader Market: Some Facts to Know
Nutanix (NTNX) closed at $66.61 in the latest trading session, marking a -1.98% move from the prior day. The stock's change was less than the S&P 500's daily loss of 0.17%. Meanwhile, the Dow
Why Adobe Systems (ADBE) Dipped More Than Broader Market Today
Adobe Systems (ADBE) ended the recent trading session at $263.99, demonstrating a -2.4% change from the preceding day's closing price. The stock's change was less than the S&P 500's daily loss of
Why Broadcom Inc. (AVGO) Dipped More Than Broader Market Today
In the latest close session, Broadcom Inc. (AVGO) was down 5.93% at $393.06. This move lagged the S&P 500's daily loss of 0.17%. At the same time, the Dow lost 0.2%, and the tech-heavy Nasdaq lost
Solana Company (HSDT) Reports Q2 Loss, Lags Revenue Estimates
Solana Company (HSDT) came out with a quarterly loss of $0.05 per share versus the Zacks Consensus Estimate of a loss of $0.02. This compares to a loss of $79.73 per share a year ago. These figures
Vivos Therapeutics, Inc. (VVOS) Reports Q2 Loss, Lags Revenue Estimates
Vivos Therapeutics, Inc. (VVOS) came out with a quarterly loss of $0.31 per share versus the Zacks Consensus Estimate of a loss of $0.42. This compares to a loss of $0.55 per share a year ago. These
Applied Materials (AMAT) Stock: A Top AI Pick After Record Q3 Results
The artificial intelligence investment story is often dominated by chip designers, data-center operators, and cloud-computing companies.
That said, Applied Materials AMAT) offers investors a
Cerenome (CNSY) Reports Q2 Loss, Misses Revenue Estimates
Cerenome (CNSY) came out with a quarterly loss of $1.31 per share versus the Zacks Consensus Estimate of a loss of $0.96. This compares to a loss of $0.25 per share a year ago. These figures are
J.B. Hunt Sees Freight Recovery, Intermodal Pricing Upside Into 2027
Key Points
- Interested in J.B. Hunt Transport Services, Inc.? Here are five stocks we like better.
- J.B. Hunt sees an early-stage freight recovery as trucking capacity tightens, demand indicators
Contango ORE Q2 Earnings Call Highlights
Key Points
- Interested in Contango ORE, Inc.? Here are five stocks we like better.
- Manh Choh production is expected to accelerate in the second half of 2026 as mining shifts to higher-grade
Itron Says Grid-Edge Intelligence Is Fueling Its Expanding Utility Opportunity
Key Points
- Interested in Itron, Inc.? Here are five stocks we like better.
- Itron is shifting beyond smart meters, with growth increasingly centered on grid-edge intelligence, software and
Can BMY's First CELMoD Approval Support Its Growth Strategy?
Bristol Myers Squibb BMY recently announced that the FDA has granted accelerated approval to iberdomide in combination with daratumumab and hyaluronidase-fihj and dexamethasone (ZDd).
The regimen